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Abstract

Prostate cancer is the most common malignancy in North American men and there
is no treatment currently available which offers a clear survival advantage to patients
with prostate cancer. We studied liposomes formulated with the fusion-associated
small transmembrane (FAST) protein, p14. In this study, we hypothesized that
therapeutics delivered in molecular targeted fusogenic liposomes will increase
intracellular delivery and specificity for prostate cancer. We demonstrated that
liposomes formulated with p14-bombesin significantly increased the delivery of
fluorescein isothiocyanate (FITC) into human prostate cancer (PC-3) cells compared
to either standard liposomes or non-targeted fusogenic liposomes. Delivery of FITC
to benign prostate hyperplasia (BPH) cells, which express low levels of the gastrin
releasing peptide receptor (GRPR), was similar for targeted and non-targeted
formulations. Specificity for GRPR was further established by knocking down GRPR
expression with siRNA. Knockdown of the receptor resulted in equivalent
intracellular delivery of the FITC with targeted and non-targeted formulations.

Keywords: Bombesin, Fusogenic Liposomes, p14, Prostate Cancer, Targeted
Therapy
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Chapter 1

1

Introduction

1.1 Overview of Prostate Cancer

Epidemiology
Cancer is a global epidemic and a major health burden with approximately 180,000 new
cases in Canada alone this year (Canadian Cancer Statistics, 2011). An estimated 75,000
Canadians succumbed to this disease in 2011 (Andriole et al., 2009; Canadian Cancer
Statistics, 2011). The term cancer in lay is a variety of diseases characterized by out of
control cell growth. Prostate cancer is the most common cancer in Canadian men with a
lifetime risk of 1 in 7 and a mortality rate of 1 in 27 (Canadian Cancer Statistics, 2011).
Prostate cancer is predominately diagnosed between men of 60-69 years of age and if
diagnosed at an early stage, 98% of cases are curable (Andriole et al., 2009; Canadian
Cancer Statistics, 2011; Gomella et al., 2011; Jacobsen et al., 1995). Although prostate
cancer has been hailed to be a “slow growing cancer”, the incidence rate has increased
more rapidly in past years (Canadian Cancer Statistics, 2011; Gomella et al., 2011). This
increase in diagnosis may be due to the aging population, the evolution of medical
technology and the routine blood screen for prostate specific antigen (PSA) (Ellison,
Gibbons, & Canadian Cancer Survival Analysis Group, 2001; Gomella et al., 2011;
Jacobsen et al., 1995). Conversely, prostate cancer is also the most common malignancy
in North American men, accounting for 10% of all cancer-related deaths in 2010
(Andriole et al., 2009; Ellison et al., 2001).
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Origin
A cancer of the glandular epithelium, prostate cancer is classified as an adenocarcinoma.
Prostate cancer risk is determined largely by age however, other risk factors are genetic
predisposition, dietary habits, and environmental stressors. Although prostate cancer is
the most common malignancy in males, the cell of origin in the gland remains unclear.
Prostate cancer has been thought to arise from cell expansion of luminal cells and the
absence of basal cells in the epithelium of the prostate gland (Lawson et al., 2010).
However, recently researchers have identified that basal cells can also initiate prostate
cancer (Goldstein et al., 2010) and therefore both the basal and luminal cells have now
been identified as prostate cancer cells of origin (Lawson et al., 2010). Even though
prostate cancer is a slow growing cancer it still maintains the ability to metastasize. Once
prostate cancer spreads, the cancer predominantly metastasizes to the bone and the lymph
nodes. This uncertainty of the biology of the prostate cancer creates uncertainties on how
to predict the outcome of the disease and therefore how to treat the disease.

Diagnostic Tools
The current diagnostic tools for prostate cancer are prostate specific antigen (PSA) test,
Digital Rectal Examination (DRE), biopsy, and Gleason Score (Karakiewicz & Aprikian,
1998). The PSA test measures the antigen quantity in the blood serum and men with
PSA levels between 4.0 and 10 ng/ml are a target population for prostate cancer
(Jacobsen et al., 1995). Prostate cancer is a heterogeneous disease that is very commonly
asymptomatic and thus identification of an increase in PSA levels can identify men with
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prostate cancer who would otherwise not know (Jacobsen et al., 1995; Ellison et al.,
2001). While raised serum PSA is a clinically adequate tumour marker, it is not specific
to prostate cancer, thus it can result in false positives (Ellison et al., 2001). As mentioned
above, the PSA test is partially responsible for the increase in incidence rate due to
identification of prostate cancer in men with localized disease who were asymptomatic
(Jacobsen et al., 1995). The PSA test was discovered in the 1980’s and since this time
the incidence rate has increased because asymptomatic men were diagnosed with prostate
cancer. Once the disease is verified by biopsy, sections are graded by the Gleason Score
which is the only critical test to help decide treatment options (Gomella et al., 2011).
Due to PSA testing and Gleason scoring, the identification of early disease, the survival
rate is near 100% (Ellison et al., 2001).

Treatment Options
As mentioned previously, prostate cancer usually grows very slowly and therefore has a
low overall risk of turning into a clinically relevant disease, giving rise to the concepts,
“watchful waiting” (Kasperzyk et al., 2011) and “active surveillance” (Gorin et al.,
2011). These approaches are for “low risk” patients with a life expectancy of 20 years
(Gorin et al., 2011). Radical prostatectomy, or removal of the prostate gland, has
significant side effects which lowers the quality of life for the patient. The extraction of
the entire gland creates an array of life altering complications such a urinary incontinence
(Doherty & Almallah, 2011) and sexual dysfunction (Siegel et al., 2001). Taken
together, surgery is not always the end result in this disease and there is evidence that
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“active surveillance” can work without adding to the mortality rate (Graversen et al.,
1990). On the other hand, there is a possibility that an aggressive cancer will be missed
and the opportunity for a life-saving surgery. Despite the inherent advantages and
disadvantages of “active surveillance” and radical prostatectomy (Bangma, 2011), it may
be safer to intervene and treat the tumour with another means. An alternative therapy
would be radiation therapy which is the use of ionizing x-ray beams to destroy the
tumour cells. However, drawback of this therapy is exposure and degradation of healthy
cells to ionizing radiation. Furthermore, chemotherapeutics are small molecule drugs
which are toxic to all proliferating cells in the body and therefore subject the patient’s
healthy cells to significant toxicity. These harmful effects of chemotherapy result in
unwanted side effects such as hair loss, nausea, and sexual and fertility dysfunction.
Most chemotherapeutic drugs do not preferentially target the tumour and therefore
subject the patient’s healthy cells to significant toxicity. Radical prostatectomy and
radiation is used for localized disease versus chemotherapy treatment for advanced
prostate cancer (Bangma, 2011; Doherty & Almallah, 2011). No treatment currently
available offers a clear survival advantage to patients with advanced prostate cancer,
highlighting the urgent need for new targeted therapeutic strategies.
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1.2 Liposomes as Therapy Vehicles

Liposomes were first described by Alec Bangham (1964) as spherical lipid particles
comprised of a phospholipid bilayer enclosing an aqueous core (Bangham & Horne,
1964). Due to their intriguing inherent resemblances to cell membranes, liposomes are
considered universal drug vehicles in the cosmetic and pharmaceutical industries (DrulisKawa & Dorotkiewicz-Jach, 2010). Liposomes have therefore gone through intense
research and development to improve drug delivery. Both hydrophobic and hydrophilic
active molecules can be encapsulated within the liposomal structure due to their unique
architecture (Liautard et al., 1991). Hydrophobic molecules are located within the bilayer
(Schwendener & Schott, 2010) whereas hydrophilic molecules are located in the core of
the particle (Liautard et al., 1991). Liposomes are inert, biocompatible particles giving
rise to the phenomenon of “drug vehicles” to improve the drug pharmacokinetics and
bioavailability. The active molecules entrapped in the core can vary from small molecule
drugs, antibiotics, nucleic acids, and peptides (Drulis-Kawa & Dorotkiewicz-Jach, 2010;
Lutsiak et al., 2002; Uziely et al., 1995; Yagi et al., 2009). The unique ability to shield
the cargo from degradative mechanisms in cells but to also protect healthy cells from
toxic drugs within makes liposomes an attractive asset to therapeutic delivery (Kaye &
Richardson, 1979; Mayer et al., 1989).
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“Stealth” Liposomes
Decades of research, have been dedicated to improving the bioavailability and tumour
uptake of liposomes. To improve the bioavailability, addition of polyethylene glycol
polymer chain (PEG) molecules are covalently attached to liposomes. PEGylation
protects the liposomes from detection of the immune system. The theory of Stealth ®
liposomes were first introduced by Allen (Allen et al., 1992) and are considered the
“second generation” of liposomal drug delivery (Immordino et al., 2006). Sterically
stable liposomes increase the pharmacokinetics of the drug and sustain a longer blood
circulation time (Allen & Hansen, 1991). PEGylated liposomes are currently in clinics to
treat a variety of different cancers including breast, ovarian and prostate (Park, 2002), one
such example is Doxorubicin encapsulated within PEGylated liposomes (commercial
name: DOXIL) (Allen & Hansen, 1991). However, it was observed by Mishra et al that
liposomes functionalized with PEG have been found to decrease endosomal escape
resulting in degradation of the cargo (Mishra et al., 2004). While addition of PEG
molecules to liposomes have a clear benefit on the systemic level, on a cellular level
PEGylation poses a clear disadvantage (Remaut et al., 2007). For example, the
therapeutic index of even these newer “second generation” formulations, is still quite low
due to non-specific uptake and endocytosis-mediated drug degradation (Figure 1.1A).
Despite the recent advancements of increasing the drug bioavailability and
pharmacokinetics, there is still suboptimal delivery of the cargo to inside the cells.
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1.3 “Fusogenic” Entities
“Fusogenic” Lipid
Another critical milestone in liposomal development was the introduction of fusogenic
moieties to avoid endosomal degradation. Once liposomes are endocytosed, the particles
are challenged by the acidic environment and thereby an escape mechanism is needed to
salvage the cargo they carry. The simplest method is incorporation of a “fusogenic”
lipid, such as a neutral helper lipid phosphatidylethanolamine (PE) (Farhood et al.,1995;
Zhou & Huang, 1994). Several groups have shown that addition of 1, 2-dioleoyl-snglycerol-3 phosphatidylethanolamine (DOPE) in their liposomes will significantly
increase the transfection of deoxyribonucleic acid (DNA) (Farhood et al., 1995; Zhou &
Huang, 1994). Zhou and Huang reported the presence of DOPE increases the DNA
transfection by 60% compared to liposomes without DOPE (Zhou & Huang, 1994). The
authors also reported that the DNA entered the cytoplasm mainly by destabilizing
endosomes and provoking endosomal escape (Zhou & Huang, 1994). Furthermore,
Farhood et al demonstrated that this endosomal release was only in the presence of high
levels of DOPE (Farhood et al., 1995). In extension of these studies, DOPE was
characterized to have a cone-like structure which adopts a hexagonal phase that disrupts
the endosomal membrane and initiating the escape into the cytoplasm (Zuhorn et al.,
2005). Taken together, DOPE acts as an endosomolytic agent depositing the cargo into
the cytosol of cells.
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“Fusogenic” Peptides
Efforts have been made to mimic methods employed by viruses for intracellular delivery
of macromolecules (Kobayashi et al., 2009). Studies have been reported using a variety
of pH sensitive peptides such as vesicular stomatitis virus proteins, phage coat proteins
proteins and shGALA to name a few (Peisajovich et al., 2002; Sakurai et al., 2011).
These viruses have evolved as an effective strategy to escape the endosomal uptake of
compounds by exploiting biological processes. There are many fusogenic peptides that
can traffic membrane impermeable compounds into the cell by endocytosis, however
only limited studies have been accomplished to incorporate these proteins within
liposomes.
VSV G protein
Previous research has successfully reconstituted an enveloped viral protein, vesicular
stomatitis virus (VSV) glycoprotein (G) protein within liposomes using Octylglucoside
(OG) dialysis (Eidelman, 1984; Metsikko, 1986; Petri, 1979). Petri et al was the first to
describe the insertion of the VSV G protein within a lipid bilayer using the OG detergent
depletion. In extensions of this study, to evaluate the fusogenic capabilities, other groups
discovered that the fusion was pH dependent (pK~4.0) and therefore the entry within
endosomes was needed for the G protein to exert its effect (Eidelman et al., 1984).
Furthermore, it was observed that, upon detergent dialysis using SM2 beads to remove
the detergent, the G protein loses fusion activity (Metsikko et al., 1986). The authors
speculate that the hydrophobic beads caused denaturation of the G protein (Metsikko et
al., 1986). Despite these inherent advantages of rapid endosomal release, the key strategy
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for improved efficiency of liposomal therapeutics would be to penetrate the cell
membrane bypassing endocytosis.
Phage Coat Protein
Phage coat proteins are examples of fusion proteins which increase the intracellular
escape from endosomes (Wang, et al., 2010). Recent studies, using a phage coat library
technique, have identified PVIII protein with specific fusion abilities toward targeted
cells (Jayanna et al., 2009). It was observed through fluorescence microscopy, that phage
liposomes were taken up by endocytosis and triggered membrane fusion in the endosomal
acidic environment (Wang et al., 2010). The authors compared their phage liposomes to
plain liposomes and visualized the perinuclear punctuate localization of the standard
liposomes compared to the diffuse distribution of the phage liposomes. The authors
postulated that the diffuse pattern was a result of endosomal escape through fusion of the
pH sensitive phage proteins to the endosome bilayer (Wang et al., 2010). Furthermore,
they verified this theory by adding an endosome acidification inhibitor (NH4CL) and
observed the entrapment of the phage liposomes within perinuclear vesicles (Wang et al.,
2010). Thereby, confirming the pH sensitive phage liposomes elicit their fusion
capabilities in the acidic endosomal environment to release their cargo intracellularly.
Despite the success of inserting these fusogenic peptides into liposomes, unsuccessful
fusion with the cell membrane was observed. These endosomal release strategies using
enveloped viruses increased the intracellular delivery compared to standard liposomes
however, the results are sub-optimal and the ultimate goal of fusion with the cell
membrane was not successful.
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1.4 P14 Liposomes
Orthoreovirus Non-enveloped Fusion Proteins
Fusion associated small transmembrane (FAST) proteins are a unique class of proteins
encoded by the genus orthoreoviruses. The five distinct species in the orthoreoviruses
genera include the avian reovirus (ARV), nelson bay reovirus (NBV), and baboon
reovirus (BBV), aquareovirus reovirus (AQV) and reptilian reovirus (RRV) (Duncan,
Murphy, & Mirkovic, 1995; Duncan et al., 2004; Gard & Compans, 1970; Shmulevitz &
Duncan, 2000). Reoviruses represent a distinct group of non-enveloped viruses that are
capable of forming multinucleated cells, syncytia (Duncan et al., 1996; Duncan et al.,
2004; Shmulevitz et al., 2003; Shmulevitz et al., 2004; Top et al., 2011). Fusogenic
reoviruses are a rare exception of non-enveloped viruses which induce cell-cell fusion
independent of virus entry and production (Duncan et al., 1996; Duncan, 1996;
Shmulevitz & Duncan, 2000). A typical phenotype for enveloped viral proteins promotes
entry of the virus into cells (Shmulevitz & Duncan, 2000). Upon infection of these
reoviruses, fusion associated small transmembrane (FAST) proteins are translocated to
the cell surface mediating cell-to-cell fusion (Shmulevitz & Duncan, 2000; Shmulevitz et
al., 2002).
The classification of the reptilian reovirus was recorded by Duncan et al as a distinct
species of the fusogenic reoviruses (Duncan et al., 2004). Even though the reptilian virus
was discovered and isolated years before from a moribund python in 1987 (Ahne,
Thomsen, & Winton, 1987), the virus was never classified as a new fusogenic species at
that time. Duncan et al established the newly identified reovirus after confirming the
virus induced extensive multi-nucleated cells (syncytium) in infected cell cultures typical
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of fusogenic reoviruses. Furthermore, the 125 amino acid fusion protein had differential
sequences compared to the other FAST proteins.

P14 FAST Protein Structure
The reptilian reovirus FAST protein was named according to the molecular weight in
kDA, p14. The authors characterized the structural motifs of the p14 protein and
revealed its own signature arrangement of a myristoylated N-terminus; however the
protein remains surface-localized (Corcoran & Duncan, 2004). Figure 1.2 illustrates the
structure of the p14 FAST protein, highlighting the N-terminal myristoylation site, the
hydrophobic path, a single transmembrane domain, and the exposed C-terminus. Further
studies indicated that the myristoylation of the N-terminal region was responsible for the
fusion capabilities (Corcoran & Duncan, 2004; Corcoran et al., 2004). It was
demonstrated that point mutations at the myristoylation site renders the p14 fusion
incompetent (Corcoran et al., 2004). Moreover, to confirm the N-terminal myristoylation
site was solely responsible for the fusion abilities, deletion of the C-terminal 10-20 amino
acids was evaluated. Overall, the extent of fusion remained unaltered, however the rate
of syncytium was slowed (Corcoran et al., 2004). Taken together these results confirm
that the post translational modification of p14 is both functional and essential for fusion
activity (Corcoran et al., 2004).
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Figure 1.1 Representation of Intracellular Cargo Delivery Using Liposomes
A) Standard liposomal technology depends on two routes for intracellular delivery; i)
non-specific leakage of the cargo out of the liposome and passive uptake by the target
cells or ii) uptake of intact liposomes into the endosomal pathway.
B) Fusogenic liposomes include the p14 FAST protein which mediates efficient
liposome-cell fusion, bypassing the endocytic pathway, depositing the cargo directly into
the target cell. The fusogenic liposomes therefore have a distinct advantage over the
standard liposomes when delivering cargo intracellularly.
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P14 Reconstituted into Liposomes
In an extension of these studies, the authors tested whether p14 protein could function on
its own to induce membrane fusion when reconstituted in liposomes (Top et al., 2005).
The p14 protein was inserted into the artificial bilayer using OG detergent depletion
method (Petri & Wagner, 1979). The authors identified the equal protein orientation by
immunofluorescence staining of both the exposed N-and C-terminus (Top et al., 2005).
The theory proposed by the authors is that exposure of the p14 N-terminal myristoylation
on the surface of the liposomes allows the p14-liposomes to interact with cell membrane
of target cells (Figure 1.1 B). Figure 1.1 demonstrates the comparison of cargo uptake
between the standard and fusogenic liposomes. The successful intracellular delivery of
the cargo using standard liposomes is based upon i) non-specific leakage of the
encapsulated cargo in the bloodstream and passive uptake by the target cells and ii)
uptake of the intact liposomes into the endosomal pathway (Figure 1.1A). The cargo
contained within standard liposomes is prone to degradation upon entry into the
endocytic pathway. For this reason, the standard liposomes are restricted to specific
cargos that posses inherent membrane penetration capabilities and the ability to withstand
the acidic environment of the endosomal pathway. However, it is hypothesized that
fusogenic liposomes fuse with the cell membrane via the N-terminal myristoylation site
allowing lipids from the cell membrane and liposomes to mix, for direct deposit into the
cell (Figure 1.1B) (Top et al., 2005).
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Figure 1.2 Schematic representing the fusogenic liposomal platform
A) The structure of p14 Fusion Associated Small Transmembrane (FAST) protein. The
p14 protein is encoded by the reptilian reovirus (RRV) and is named according to the
molecular weight in kDa. The 125 residue structure contains; N-terminus myristoylation
site (green triangles), the hydrophobic patch (yellow half circle), transmembrane domain
(purple rectangle), basic region (blue rectangle) and the C-terminus polyproline motif
(red half circle). Reprinted from (Corcoran & Duncan, 2004; Top et al., 2005).
B) Representation of fusogenic liposomes; p14 spans the lipid bilayer displaying either
the N- or C- terminus on the surface of the liposome. The green circles represents the
“cargo” (example in this thesis: fluorescein isothiocyanate (FITC)) encapsulated within
the core of the liposome.
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P14 Induces Lipid Mixing with the Cell Membrane
To test the lipid mixing hypothesis, Top et al performed a FRET, (fluorescence resonance
energy transfer) assay and measured the fluorescence by flow cytometry (Struck et al.,
1981; Top et al., 2005). The increased cell fluorescence over time was observed with
p14-liposomes whereas this increase was not observed with standard liposomes (Top et
al., 2005). To ensure these results were due to lipid mixing, the authors added
lysophosphatidylcholine, a monoacylated fatty acid known to inhibit membrane fusion
(Chernomordik & Kozlov, 2003; Top et al., 2005). The addition of
lysophosphatidylcholine efficiently inhibits lipid mixing of the p14-liposome and the
cells, confirming the lipid mixing hypothesis (Top et al., 2005). The exceptional
structural features of p14 initiate liposome-cell lipid mixing identifying a potential
liposomal carrier which bypasses endocytosis.

P14 Liposomes Intracellular Delivery
Cytoplasmic delivery of therapeutics is highly desirable, however very difficult to
achieve because poor performance of standard liposomes and previously described
fusogenic peptides. The ideal delivery system would bypass the endocytic pathway and
deliver the cargo directly to the cytosol of cells. The unique feature of the p14 FAST
protein has the potential to solve this drug delivery caveat. Mader et al demonstrated the
ability to deliver a cytotoxic peptide directly to the cell cytoplasm via p14-liposomes
(Mader et al., 2007). Bovine lactoferricin (LfcinB) is a cationic peptide that kills
leukemia cells. In the presence of endocytosis inhibitors, LfcinB on its own was not
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internalized by receptor mediated endocytosis (Mader et al., 2007). However, when
LfcinB was delivered using p14-liposomes, the release was directly into the cytosol
causing cell death (Mader et al., 2007). The extensive studies on p14 and how it interacts
within a lipid bilayer has given critical insight into a novel fusogenic liposome that does
bypass endocytosis, however penetrates the cell membrane.

17

1.5 Passive Targeting
Another interesting property of liposomes is their natural ability to accumulate at the
tumour site. Healthy, normal blood vessels are comprised of endothelial cells that are
bound together by tight junctions and therefore inhibit large particles from leaking out of
the vessel. Consequently, the tight junctions of tumour vessels are compromised and
particles are able to leak through the leaky cell fenestrations. This process of passive
targeting occurs because of the various anatomical anomalies that occur in tumour
vessels, such as leaky vasculature and poor lymphatic drainage, termed enhanced
permeability and retention effect (EPR) (Matsumura & Maeda, 1986). Matsumuri et al
studied the EPR effect by testing the accumulation of macromolecules in tumour tissue
upon intravenous injections of radioactive labeled protein in a mouse model (Matsumura
& Maeda, 1986). The authors were able to identify the collection of labeled
macromolecules in the subcutaneous tumours and concluded that the vasculature near the
tumour had been compromised and these macromolecule accumulations were due to
passive targeting of the EPR effect (Matsumura & Maeda, 1986). A key consideration
for the design of nanocarriers to take full advantage of the EPR effect is the size of the
particle (Yu et al., 2010). It was identified that particles of < 200 nm in diameter are the
preferred size to rapidly accumulate at tumour sites via the EPR effect (Liu et al., 1992).
Furthermore, PEGylated liposomes reduce the recognition by the RES and long
circulating liposomes are required for extravasation (B. Yu et al., 2010).
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Taken together, liposomes were shown to extravasate and accumulate selectively in
tumour interstitium of a variety of murine models as a result of EPR effect. Figure 1.3
demonstrates the differences between liposome accumulations in tumour versus normal
vasculature, highlighting the effects of the EPR effect. Therefore, liposomes could
accumulate over time in solid tumours after intravenous administration. Moreover,
current anti-cancer therapeutics, such as DOXIL®, are passively targeting tumours and
by virtue of the EPR (Kuijpers et al., 2000). However, passive targeting cannot promote
further uptake by cancer cells once they have arrived. Therefore, further investigation of
targeted receptor mediated uptake would increase the therapeutic window of anti-cancer
drugs.
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Figure 1.3 Schematic of the enhanced permeability and retention effect (EPR)
Normal vasculature permits liposomes to pass between the endothelial cells, whereas the
EPR effect results in leaky vasculature where liposomes <200 nm in diameter can pass
between the junctions and act on the cancer cells.
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1.6 Active Targeting
“Smart Particles” or “Magic Bullets” are terms coined for the phenomenon that
therapeutics can selectively target and kill cells without harming the neighboring cells.
Direct targeting of cancer cells using liposomes has the potential to treat cancer with
higher efficiency than standard anti-cancer therapeutics. There are key points to consider
when creating targeted nanoparticles; 1) a target should be in sufficient quantity
(overexpressed) providing a good opportunity to bind to the target 2) ligand attachment
should be attached to the surface of the particle and 3) a target should facilitate
internalization (Maruyama, 2011).

Prostate Targeting Ligands
Direct targeting of prostate cancer is a strategy towards killing the cancerous cells while
decreasing healthy bystander cell toxicity. Various types of targeting ligands have been
exploited for directing liposomes to prostate cancer (Table 1.1). Attention has been
directed towards targeting liposomes to cell integrins, as they have significant expression
on tumour vasculature. Such peptides that would bind to αvβ3 and α5β1 integrins are
promising ligands to target a variety of different cancers, including prostate (Arap et al.,
1998; Demirgoz et al., 2008). Demirgoz et al examined the targeted efficiency of the
PR_b functionalized liposomes to α5β1 integrins (Demirgoz et al., 2008). The authors
demonstrated that liposomes functionalized with PR_b improved the cytotoxicity
displayed by the total higher fluorescent intensity for prostate cells in stages of apoptosis
(Demirgoz et al., 2008). Despite recent advancements with targeting the αvβ3 integrins
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with RGD decorated liposomes, the studies using PR_b liposomes demonstrated a clear
advantage over the RGD targeting techniques (Demirgoz et al., 2008). Other, attractive
targets for cancer are the transferrin and folate receptors as they are both highly up
regulated on tumours (Gabizon et al., 1999; Singh, 1999; W. Yu et al., 2004). While
these ligands target a variety of different cancers, the anti-PSMA ligand is specific for
prostate cancer. Expressed on the surface of prostate cancer cells, the prostate specific
membrane antigen is used in targeted delivery. Ikegami et al constructed liposomes
containing anti-PSMA for targeting gene therapy and concluded that the transfection was
higher in the targeted liposomes than that of normal liposomes (Ikegami et al., 2006).
There are many different targeted ligands that can be conjugated to the surface of
liposomes; however, it is the method on which the ligand is supported that will prove to
be efficient.
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Table 1.1 Prostate Cancer Targeting Ligands for Liposomes
Type

Targeting
Ligand

Receptor

References

Peptide

RGD
PR_b

αvβ3
α5β1

(Arap et al., 1998)
(Demirgoz et al., 2008)

Protein

Transferrin

Transferrin
Receptor

(Singh, 1999; W. Yu et al.,
2004)

Antibodies

Anti-PSMA

PSMA Receptor

(Ikegami et al., 2006)

Small
Molecules

Folic Acid

Folate Receptor

(Gabizon et al., 1999)
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Attachment of the Targeting ligand
The construction of a targeted particle requires the conjugation of the ligand to the
surface of the liposomes. The two methods deployed for the attachment of ligands are
either covalent or noncovalent coupling (Nobs et al., 2004). Ligands can either be
assembled with phopholipid headgroups of non-PEGylated liposomes or can be anchored
to the liposomes via PEGylated chains (Maruyama, 2002; Sofou, 2007). Different
covalent coupling strategies include thioether bonds, disulfide linkage, crosslinking, and
hydrazone bond (Hansen et al., 1995; Nobs et al., 2004). Despite these efforts to attach
ligands to the surface of liposomes, there is not an optimal covalent coupling reaction.
This is due to the drawbacks of the number of crucial parameters, such as the length, type
and localization of the crosslinker. Covalent reactions also require chemical reagents
which could potentially alter or damage the ligand or the liposome (Hansen et al., 1995).
Non-covalent coupling is beneficial over covalent coupling because there is no need for
harsh chemicals (Nobs et al., 2004). However, this method is not widely used because of
the weak interaction of ligand on the liposomal surface (Duarte et al., 2011; Nobs et al.,
2004). Therefore, targeted proteins that can be inserted into the bilayer of the liposomes
would be optimal, due to these drawbacks of coupling to the surface of the liposomes.
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1.7 Bombesin Targeting Peptide
The development of anti-cancer therapeutics that can be targeted to specific receptors,
over-expressed in prostate cancer, but sparse the uptake in normal tissue, is critical.
Receptors for the gastrin releasing peptide are over-expressed in several human tumours,
including pancreatic, small lung carcinoma, breast, and prostate (Varvarigou et al., 2004).
Originally isolated from the skin of the fire bellied frog Bombina bombina, Bombesin is a
14 amino acid peptide (Anastasi et al., 1971). Although the GRPR is frequently
expressed by many tumour types there are three other bombesin receptor subtypes that
bombesin binds to, NMB, BRS-3, and BB4 (Reubi et al., 2002). Furthermore, prostate
cancer cells express approximately 48000 GRPR per cell (Aprikian et al., 1996). Many
radiolabelled bombesin analogues have been created for SPECT and PET modalities to
target the GRPR, allowing for novel prostate cancer imaging probes (Ananias et al.,
2008; Safavy et al., 1997). Even though there have been no studies performed
conjugating bombesin to liposomes there has been however, bombesin attachment to
polymeric (Lee et al., 2010) and viral nanoparticles (Steinmetz et al., 2011). Current
studies in our laboratory have demonstrated the tumour homing efficiency of bombesin
virus particles by intravital imaging in a xenograft avian embryo model of human
prostate cancer (Steinmetz et al., 2011). We validated bombesin targeting to a human
prostate cancer cell line (PC3) in vitro by confocal microscopy. Non-targeted viral
nanoparticles did not bind to PC3 cells at an appreciable level compared to bombesin
particles (Steinmetz et al., 2011). To ensure that binding of the bombesin particles was
specific for the GRPR a 10-fold excess of free bombesin peptide was added to block the
particles, resulting in a dramatic decrease in bombesin-viral uptake (Steinmetz et al.,
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2011). This previous research in our laboratory suggests that bombesin would be suitable
for functionalizing liposomes to target prostate cancer.
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1.8 Nucleic Acid Delivery Using Liposomes
Liposomes have been used as carriers for many different applications and are not limited
by the cargo they carry. As mentioned previously, nucleic acids can also be packaged
within liposomes to improve the delivery of deoxyribonucleic acid (DNA) and small
interfering ribonucleic acid (siRNA). Traditional transfection reagents such as
Lipofectamine™ are some of the most popular transfection reagents utilized for in vitro
as they are comprised of a cationic lipid, 1-2, 3-dioleyloxy-propyl- trimethylammonium
chloride (DOTMA) (Felgner et al., 1987). Cationic formulations facilitate the functional
delivery into cells as they complex with the negatively charged nucleic acids. These
traditional transfection reagents however, cannot be used in vivo because they are
unstable in plasma and are eliminated rapidly from the blood. Consequently, neutral
liposomes have been used instead. However, their encapsulation efficiency is low. Thus,
the development of a liposomal carrier that provides physical containment of the nucleic
acids is needed to overcome the problems associated with existing cationic carriers (Yagi
et al., 2009).

Wrapped Liposomes
The development of novel liposomes “Wrapsomes” (WS) or “Wrapped Liposomes”
(WL) were constructed using an innovative procedure (Yamauchi et al., 2006). The
strategy was to increase the nucleic acid encapsulation efficiency by identifying an
alternative liposomal formulation (Yamauchiet al., 2006). Complexes were prepared by
incorporating a cationic lipid core in order to complex with the siRNA within a neutral
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liposomal bilayer to increase the serum stability (Yamauchi et al., 2006). Yagi et al also
adopted this unique lipid formulation and proved that WS nanoparticles stabilize siRNA
decreasing the degradation in serum (Yagi et al., 2009). The authors also evaluated the
WS uptake in vivo and reported inhibition of tumour growth (Yagi et al., 2009).
Wrapped liposomes are the first to our knowledge to demonstrate efficient nucleic acid
delivery in vivo.

Heparin Releases DNA from Liposomes
The strong interaction with cationic lipids to DNA creates difficulty when quantifying
DNA encapsulation within liposomes (Gershon et al., 1993). Using conventional
methods for quantifying DNA, such as Ethidium Bromide (EtBr), results in a decrease of
intercalation because the cationic lipids displace the binding of the agent. In this
vicinity, a compound needs to be added to substitute the lipids from the DNA before
DNA quantification is performed. Addition of anionic polymers, such as heparin and
dextran sulfate, is commonly used to displace the cationic lipids from the DNA (Tsai,
Furstoss et al., 2002; Xu & Szoka, 1996; Zelphati & Szoka, 1996). Anionic polymers
have a 2 fold greater charge density than DNA which explains why cationic lipids
preferentially associate with the polymers over DNA and quantification can be performed
(Casu, 1985). Previous studies demonstrated that heparin and dextran sulfate
substantially released plasmid DNA (>50%) from cationic liposomes before quantifying
with EtBr (Xu & Szoka, 1996; Zelphati & Szoka, 1996).
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1.9 Hypothesis and Objectives
Given the structure of p14, we hypothesize that the incorporation of bombesin targeting
peptide will be tolerated at the C-terminal end of p14, so that liposomes with cell-specific
and fusogenic properties will increase the intracellular delivery of therapeutics and
specificity for prostate cancer.
In this dissertation my objectives are as follows:
1) Establish the intracellular delivery of liposomes formulated with p14 protein (nontargeted)
a) Calculate the syncytia index of p14 expression in human fibrosarcoma
(HT1080) cells
b) Determine the p14 localization in syncytium formation
c) Verify the fusogenic liposome platform by comparing the intracellular delivery
of FITC compared to standard liposomes in human breast cancer (MDA-MB
231), human fibrosarcoma (HT1080), and prostate cancer (PC3) cells
2) Create a targeted fusogenic protein by conjugating bombesin to the C-terminus of the
p14 to target the gastrin releasing peptide receptor overexpressed on prostate cancer
a) Generate a p14-bombesin plasmid and test the functionality using a fusion
assay
c) Create a recombinant baculovirus to purify the p14-bombesin protein and
verify the active protein
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3) Assemble p14-bombesin liposomes and assess the delivery of fluorescein
isothiocyanate (FITC) to prostate cancer cells
a) Insertion of the active proteins and test the uptake of the targeted liposomes on
PC3 cells
4) Evaluate the specificity of the targeted fusogenic liposomes
a) Evaluate the uptake of p14-bombesin liposomes on benign prostatic
hyperplasia (BPH) cells
b) Receptor blocking analysis
c) Knockdown of the GRPR using siRNA
5) Evaluate the intracellular delivery of nucleic acids
a) Encapsulate plasmid DNA using a novel wrapped liposomes carrier
b) Calculate the entrapment efficiency of the DNA within the WS
b) Assess the transfection efficiency of the p14-wrapsomes containing GFP

The preliminary results from the targeted fusogenic liposomes developed here indicate
the novelty and the specificity of this therapeutic vehicle for prostate cancer. Although
the data is ongoing, it provides a basis for a therapeutic carrier with the ability to increase
the therapeutic efficacy of small molecule drugs and nucleic acids. The efforts made here
contribute to the overall goal to deliver therapeutics to prostate cancer using the platform
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developed in this dissertation. The fifth objective was to establish the efficacy of nucleic
acid delivery. However, the results for plasmid DNA delivery are preliminary and the
sample size is small. The data included in this thesis is a means to show the potential of
such a platform for different uses.
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Chapter 2

2

Materials and Methods

Cell culture
Spodoptera frugiperda insect cells (sf21) purchased from ATCC were grown in either a
monolayer or in suspension. Adherent sf21 cells were grown in Graces 1x media (Gibco)
supplemented with 10% fetal bovine serum (FBS) (Multicell), L-Glutamine (Multicell)
and 10, 000 IU/ml penicillin and streptomycin (Invitrogen) at 27 oC. The suspension sf21
cells were grown in SFII 900 (Gibco) media supplemented with 3% FBS at 27 oC and
rotated at 127 RPM. All of the following cells were purchased from ATCC; MDA-MB
231 Breast Cancer, Human Fibrosarcoma (HT1080) and HT1080 cell stably transfected
with td-tomato (HT1080td-tom), and Prostate Cancer (PC3). MDA-MB 231 and
HT1080/td-tom were grown in a monolayer with Dulbecco’s Modified Eagle’s Medium
(DMEM) (Multicell) and PC3 cells were grown in F12K media (Multicell). The above
medium was supplemented with 10% FBS and 10, 000 IU/ml penicillin and streptomycin
and incubated at 37oC in a humidified 5% CO2 atmosphere. Benign Prostatic Hyperplasia
(BPH) cells were a generous gift from Dr. Michael Cox, VGH) were grown as
monolayers in low FBS 5% DMEM in the same conditions as the MDA-MB 231,
HT1080 and PC3 cells. Quail Fibrosarcoma Muscle cells (QM5) cells were isolated and
cultured in M199 media as described by Tran et al., (Tran et al., 2009).
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Antibodies
The following antibodies were used in this study: β tubulin mouse mAb (SIGMA),
Gastrin Releasing Peptide Receptor (GRPR) rabbit mAb (Abcam), and p14 rabbit mAb (a
gift from Dr. Roy Duncan’s lab).

Western Blot Analysis
For analysis of GRPR, 80% confluent cultures of PC3, PC3 knockdown and BPH cells in
6 well plates were washed twice with 1x phosphate buffered solution (PBS) and detached
from the dish with a sterile cell scraper. Samples were collected into microcentrifuge
tubes and centrifuged at 14000 rpm for 5 minutes and then lysed with cold NP40 lysis
buffer (1 % NP-40, 50mM Tris-HCL, pH 8.0, 150 mM NaCl) containing protease
inhibitor cocktail (Roche) for 10 minutes on ice, centrifuged for another 14000 rpm for
10 minutes. Protein was collected and the concentrations were measured by the Bradford
protein assay (BioRad). 10 µg of total protein was denatured in DL-Dithiothreitol (DTT)
(Sigma-Aldrich) at 95oC for 5 min and was loaded into 12 % gels, separated using SDSPAGE gels and transferred to a polyvinylidene difluoride (PVDF) membrane (GE
Healthcare). Membranes were blocked for1hr at room temperature in 5% skim milk
(Bioshop) in TBST (10mM Tris base pH 7.4, 150mM NaCl, and 0.1% Tween 20). To
probe for rabbit GRPR pAb (1:500), the rabbit p14 pAb (1:1000) or mouse β tubulin
mAb (1:1000) in 5% skim milk in TBST was placed on the membrane overnight at 4oC.
After three washes of TBST, horseradish peroxidase conjugated secondary antibody,
either anti-rabbit or anti-mouse (1:10,000 in 5% skim milk in TBST) (GE Healthcare)
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was incubated1hr at room temperature followed by five washes with TBST. The
presence of protein was evidenced by using the enhanced chemiluminescence (ECL)
detection kit (GE Healthcare). All bands were quantified by densitometry using Image J
gen analysis took and expression was reported relative to Tubulin expression.

Creation of recombinant p14-bombesin
A recombinant baculovirus encoding p14-bombesin was created using the Bac-To-Bac
Baculovirus Cloning and Expression System (Invitrogen). Bombesin was cloned into the
pFastBac1-p14 (generous gift from Roy Duncan (Top et al., 2005) transfer vector by
PCR amplification under the control of the polyhedrin promoter between the restriction
enzyme (RE) cleavage sites BamH1 and Xho1 (NEB). The following primers (Forward:
5’-GCGGATCCATGGGGAGTGGACCCTCTAATTTCG - 3’; Reverse: 5’GCCTCGAGTTACATCAAGTGACCCACTGCCCAACTGATTCCCCAGCCTCTGCT
CGTGATGGTGGTGATGGTGCTTGTTCGTCGTCATC-3’) purchased from Sigma
was incorporated an in-frame enterokinase-cleavable C-terminal 6x histidine tag, the
entire bombesin sequence, and restriction sites for BamH1 and Xho1 into the PCR
product for insertion into pFastBac1-p14. After purification (Bio Basic Inc. Gel
extraction and PCR product purification kits) and enzymatic digestion with BamH1 and
XHO1 (NEB), the construct was ligated into pFastBac plasmid under the control of the
polyhedrin (PP) promoter, sequenced and transiently expressed into HT1080 cells. The
sequences were confirmed by DNA sequencing analysis at Robarts Research Institute.
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Plasmid Fusion Assay
HT1080td-tom and QM5 cells were seeded in 12 well plates to 70-80% confluency in
DMEM and M199 media containing 10% FBS for 24 hours. The pFastBac-p14 and
pFastBac-p14-bombesin were incubated with Lipofectamine 2000 (Invitrogen) as
recommended by the manufacturer and added to cells in a ratio of 1 µg of DNA: 2 µl of
Lipofectamine 2000 in serum free conditions and incubated at 37oC. After 4 hours media
was replaced with serum containing DMEM and M199. At the 8-10 hour time point the
HT1080td-tom cells were analyzed using fluorescent microscopy. The QM5 cells were
stained with CellTracker™ Green (Invitrogen) following manufacture guidelines and
visualized using epifluorescence microscopy. The QM5 cells were also analyzed using a
flow cytometry (Union Biometric) and staining the nuclei with SYTOX® green. The
QM5 cells were detached from the surface using trypsin (Gibco) and cell suspensions
were centrifuged for 1400 rpm for 5 minutes. Cell pellets were resuspended in 1X PBS,
centrifuged for another 1400 rpm for 5 minutes before cells were fixed using 4%
formaldehyde (Bioshop) solution in 1X phosphate buffered solution (PBS) for 10 minutes
on ice. Fixed cells were centrifuged for 5 min at 1400 rpm. The fixative solution was
then discarded and the pellet was washed 2x with 1X PBS. The cell pellet was stained
using SYTOX® green (Invitrogen) according to manufacturing guidelines. The cell
pellet was resuspended in PBS + 2% FBS and analyzed using flow cytometry.
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Recombinant p14-bombesin Baculovirus
Following the Invitrogen’s Bac-to Bac Baculovirus Expression systems, DH10αBac
Escherichia coli (E.coli) (Invitrogen) cells contain a baculovirus shuttle vector (bacmid).
Site-specific transposition of the pFastBac1-p14- bombesin expression cassette into the
bacmid creates a recombinant baculovirus that was isolated from E.coli using standard
mini-prep kit (Qiagen), and subjected to (0.5%) agarose gel electrophoresis for 1-2 hours
at 125 volts. PCR analysis of the transposition region of the recombinant bacmid using
M13/pUC forward and reverse primers (Life Technologies) was used to confirm insertion
of the p14-bombesin open reading frame. The mini-prep p14-bombesin bacmid DNA
and Cellfectin® (Life Technologies) in sf21were used to transfect 4 x 106 sf21 cells for 5
hours at 27 C. The transfection medium was removed and replaced with sf21
supplemented with 10% (FBS). After 3 days at 27 C, the recombinant baculoviruscontaining supernatant was harvested and passaged 3 times in Sf21 cells.

Plaque Assay
The recombinant p14-bombesin baculovirus titer was obtained by the plaque assay
following the Bac-to-Bac recombinant guidelines (Invitrogen). The plaque assay is used
to determine the viral titer as plaque forming units per ml (pfu/ml), in order to determine
the amount of virus used to infect insect cells for protein production. Healthy (>95 %
viable) adherent sf 21 cells were seeded in 6 well plates (2 x 106 cells) and allowed to
adhere for 1hr. Cell monolayers were infected with viral serial dilutions of low ratio p14bombesin virus and an overlay of agarose medium mixture (Grace’s 2x Insect media
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(Gibco), 10% FBS and low grade 4% agarose (Bioshop)) was added to the monolayers to
keep the cells stable and limits the spread of virus. Once the agarose medium has
solidified, plates were placed in a humidified chamber for 5-10 days. Plaques (or
clearings in the monolayer were visualized by inverting the plates. When an infected cell
produces virus it eventually lyses and thus only adjacent cells become infected. Each
group of infected cells is called a plaque, or a clearing in the monolayer of sf21 cells.
Each plaque represents a single virus and thus the virus can be counted to determine the
viral titer (pfu/ml) of the virus stock.

Protein Purification
Sf21 cells were grown in 3L suspension cultures to a cell density of approximately 4 x
106/ml and then infected with recombinant baculovirus at a MOI of 0.05 to 2.0, and
shaken 127 RPM. At 24 or 48 h post-infection (~20% dead cells), infected cells were
harvested and centrifuged at 150 x g for 20 minutes at room temperature. The resulting
cell pellet was lysed with extraction buffer (50 mM sodium phosphate, 300 mM NaCl,
1.6% Igepal, and pH 7.0) plus protease inhibitors (200 nM aprotinin, 1 μM leupeptin, and
1 μM pepstatin). Insoluble debris was pelleted and the supernatant, containing p14 or
p14-bombesin, was then added to TALON® Metal Affinity Resin (Clontech) and shaken
gently for 3 hours at 4o C for initial purification. The resin was washed with extraction
buffer twice to remove unbound protein and the p14 or p14-bombesin was eluted from
the resin with elution buffer (50 mM sodium phosphate, 300 mM NaCl, 150 mM
imidazole, 1.6% Igepal, pH 7.0). The elute was dialyzed against 50 mM HEPES, 150mM
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NaCl, 1.6% Igepal, pH 7.0) at 4 o C for 12 h and further purified using HiTrap SP HP
(Sepharose High Performance column) (GE Healthcare) ion exchange columns
(Amersham Pharmacia Biotech). The column was washed with four different buffers;
Buffer 1 (50 mM HEPES, 185 mM NaCl, 1.6% Igepal, pH 6.8), Buffer 2 (50 mM
HEPES, 1 M NaCl, 1.6% Igepal, pH 6.8), Buffer 3 (50 mM HEPES, 185 mM NaCl, 1.6%
Igepal, pH6.8), Buffer 4 (50mM HEPES, 185 mM NaCl, 1.6% OG, pH 6.8). The p14 or
p14-bombesin proteins were eluted from the column using 50 mM HEPES, 300 mM
NaCl (or 450 mM for p14), 1.6% OG. The p14 or p14-bombesin concentration was
determined by the BIO-RAD DC protein assay (BIO-RAD) and routinely adjusted to
approximately 1 to 1. 5 mg/ml. The purity of the proteins and N-terminal myristoylation
was estimated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDSPAGE) using silver stained 12% polyacrylamide gels.

Protein Fusion Assay
The QM5 cells were seeded at approximately 80% confluency in a 12 well plates and
allowed to adhere overnight. 4 µg of purified protein (p14 and p14-bombesin) was
delivered using 3µl Lipofectamine (Invitrogen) for 4 hours in serum free conditions. The
media was replaced with fresh supplemented media and incubated for 4 hours till the
assay is complete. The syncytia formation was visualized in a similar technique as the
vector fusion assay using CellTracker™ Green.
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Assembly of Liposomes
All lipids were purchased from Avanti Polar Lipids Inc.; 1, 2-dioleoyl-sn-glycerol-3
phosphatidylcholine (DOPC), 1, 2-dioleoyl-sn-glycerol-3 phosphatidylethanolamine
(DOPE), dimethylaminoethane-carbamoyl cholesterol (DC-chol) and cholesterol (chol).
Liposomes were prepared by mixing lipids dissolved in chloroform DOPC: DOPE: DCchol: chol, molar ratios of 60:30:4:6 in a round bottom flask with glass beads. Small
glass beads were added to ensure even distribution of the lipid film upon rotary
evaporation. The chloroform was evaporated for 1-2 hours using a vacuum with a rotary
evaporator devise (Buchi). The lipid film was rehydrated with 1X PBS or 10 000 MW
1mg/ml fluorescein isothiocyanate (FITC) (Sigma) diluted in 1X PBS and added to the
lipid thin film and vigorous shaking (2700rpm) for 1 hour at room temperature.

Sizing
The Avestin® extrusion apparatus is assembled and washed with methanol to dissolve
any residual lipids and washed extensively with 1X PBS. To reduce the particle size the
liposome emulsion is passed back and forth between the two Hamilton syringes
containing polycarbonate filters (100nm pore size) 21 times. Sonication uses sonic
energy to disrupt liposome emulsions into single membrane liposomes with diameters 90120 nm. Liposome diameter was determined by dynamic light scattering (DLS) and
ranged from 90-140 nm. Liposomes were stored at 4oC and were used within two weeks.
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Proteoliposome Preparation
For a 1 mL liposome preparation we insert 350 g of purified protein into 20 mM
liposomes (pre-extruded to 100nm using the Avestin Extrusion apparatus) using a
detergent depletion method. The purified protein is reconstituted into the liposomes by
mixing equal volumes of n-Octyl b-D-glucopyranoside (OG) (Bioshop) with the protein
and the liposomes. The mixture was rocked for 45 minutes at 4°C. The OG was
removed with overnight dialyses at 4oC (18000 MW cutoff) with 3 changes of PBS and
Bio-Beads SM-2 Absorbent (BioShop) to remove the residual detergent.

Liposome Uptake Studies
MDA-231, HT1080, PC3, and BPH cells were plated at 80% confluency in 6 well plates
and grown overnight. The cell monolayer was replaced with cold PBS and cooled to 4oC
for 15 min. The liposomes were incubated on the cells (1mM) at 4oC for 60 min. After
60 min incubation, the cells were washed with PBS and pre-warmed (37oC) for 60 min to
initiate delivery of liposomal cargo. After 60 min, the cells were collected and analyzed
depending on the application.

Receptor Blocking
PC3 cells were incubated with excess free bombesin peptide (Purified in Dr. Len Luyt
Chemistry lab) 10 min before the liposomal treatments on cells.
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siRNA
Dharmacon predesigned sequence for the gastrin releasing peptide receptor (GRPR)
small interfering RNA (siRNA) was purchased. 20 nM GRPR siRNA was transfected
with jetPRIME™ (Polyplus) following manufacturer guidelines. The scrambled siRNA
used as a negative control siRNA was purchased from Qiagen.

Wrapsomes
1, 2-dioleoyl-3-trimethylammonium-propane (DOTAP) lipid (~5.6 mM concentration
determined by the calculation in Appendix B) purchased from Avanti Lipids was added
to a round bottom flask with 400 µl of chloroform and small glass beads were added to
ensure even distribution of the lipid film upon rotary evaporation. The chloroform was
evaporated for 1-2 hours using a vacuum with a rotary evaporator devise. The lipid film
was rehydrated with 100-500 µg of pcDNA 3.1-GFP (Midi-prep quality DNA) diluted
in 1X PBS to a final volume of 1ml and vigorous shaking (2700rpm) for 1 hour at room
temperature. The DOTAP-DNA core was then added during the hydration step of the
assembly of liposomes described above and the same insertion protocol was used to
reconstitute p14 protein within the bilayer.

Quantification of DNA Encapsulation
DNA encapsulation of pcDNA 3.1-GFP in WS was determined using the Quant-iT™
Pico green® ds DNA kit (Invitrogen) following manufacturer guidelines. Heparin
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sodium salt (Bioshop) was also added to dissociate the DNA from the DOTAP core in
order for the Pico green® to stain the DNA. Using the microplate protocol the samples
were excited at 480 nm and the fluorescence emission intensity was measured at 520 nm
using a spectrofluorometer.

Wrapsome Transfection
Human fibrosarcoma (HT1080) cells were seeded in 12 well plates at 60% confluency
and allowed to adhere over night. 1 µg of standard and p14-wrapsomes pcDNA 3.1-GFP
were incubated on the cells while Lipofectamine™ was used as a positive control.

Flow Cytometry
After liposomal treatment, the cells were detached from the surface using trypsin and cell
suspensions were centrifuged for 1400 rpm for 5 minutes. Cell pellets were resuspended
in 1X PBS, centrifuged for another 1400 rpm for 5 minutes before cells were fixed using
4% formaldehyde solution in 1X PBS for 10 minutes on ice. Fixed cells were centrifuged
for 5 min at 1400 rpm. The fixative solution was then discarded and the pellet was
washed 2x with 1X PBS. The cell pellet was resuspended in PBS + 2% FBS and
analyzed using flow cytometry (Union Biometrica Biosorter).
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Confocal Microscopy
The cells were seeded onto glass coverslips at a confluency of 80% and incubated with
liposomes with the above cargo uptake studies. The cells were washed and fixed with
4% formaldehyde solution in PBS for 10 minutes at room temperature. After 2-3 washes
with PBS, the cells were incubated one hour at room temperature with PBS- 1% BSA
with or without 0.1% Triton X-100 (BioShop) depending on the need for intact
membranes. Nuclear staining with DAPI and actin filaments stained with phalloidin.
Confocal images were taken using 20x objective or an oil 63x objective in a spinningdisk confocal microscope, using a specialized instrument (Quorum Technologies)
comprised of an upright Zeiss Axio Examiner Z1, LUDL filter wheels and large format
motorized stage, a Yokogawa spinning disk head and a Hamamatsu 9100–12 Image EM
CCD camera, controlled by Volocity (Improvision). Fluorescence images were further
processed and analyzed using Volocity.

Statistical Analysis
All statistical analysis was performed in GraphPad Prism® with One-Way ANOVA and
Tukey’s multiple comparisons post-test with a statistical significance p<0.05.
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Chapter 3

3

Results

3.1 Objective 1: Evaluation of Intracellular Delivery of
Fusogenic Liposomes Formulated with p14-protein
(non-targeted)
A syncytia assay of pFastBac-p14 in human cancer cells reveals cell membrane
expression of p14 which induces cell to cell fusion in HT1080 cells comparable to Vero
and QM5 cells previously examined
Calculation of the syncytial index in a time course fusion assay in HT1080 cells
Prior to developing a targeted fusogenic liposome, testing needed to be complete to verify
previous studies and to establish standard assays with the native p14 protein. Preceding
comprehensive studies characterizing the expression of p14 was successfully conducted
in Vero and Quail Fibrosarcoma (QM5) cells (Corcoran & Duncan, 2004; Duncan et al.,
2004). Vero cells were originally isolated from kidney epithelial cells from the African
green monkey and are commonly used as host cells for growing viruses (Ito et al., 1964).
Furthermore, QM5 cells lines are one of the preferred cell lines used in the propagation of
avian reovirus dissemination (Tran et al., 2009). Duncan et al used Vero and QM5 cells
when studying the propagation of the reptilian reovirus, discovering multinucleated cell
formation (syncytia) similarly found with the avian reovirus (Duncan et al., 1996;
Duncan et al., 2004). Our first aim was to determine if this phenomenon would occur if
we transfected a plasmid containing the p14 sequence, pFastBac-p14 (generous gift from
Dr. Roy Duncan), in a human cancer cell line. In this study, we discovered that
expression of p14 in human fibrosarcoma td-tomato (HT1080td-tom) cells also induces
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syncytia formation comparable to the results Duncan et al demonstrated in Vero and
QM5 cells (Figure 3.1A) (Duncan et al., 1996; Duncan et al., 2004). The fluorescent
microscopy images detail syncytial formation arises at 8hr post transfection (Figure 3.1
A&B). The results from Figure 3.1A demonstrate that the rate of syncytia formation is 810 hrs and figure 3.1B is a quantification of the syncytia formation using a manual cell
counting approach. By staining the nuclei with DAPI and using a cell line that stably
expresses a red fluorescent protein (Td-Tomato), we were able to count the number of
nuclei per syncytium in five random fields of view to determine the number of nuclei
present in syncytium.

P14 is a responsible for syncytia formation and is surface localized
To ensure p14 expression is responsible for the cell to cell fusion, immunostaining of
permeabilized p14-transfected cells revealed numerous punctate regions radiating out to
the plasma membrane. A p14 polyclonal antibody was used to stain the cells and
antibody distribution was detected by immunofluorescence microscopy using an Alexa
Fluor 488 secondary antibody (Figure 3.1 C). The p14 distribution had high fluorescence
signal at the cell surface confirming membrane localization of p14 was responsible for
the fusion of the HT1080 cells resulting in the syncytia formation (Figure 3.1 C).
These results in HT1080 cells are consistent with previous research in Vero and QM5
cells confirming that p14 is localized at the cell membrane to induce cell-to-cell fusion
creating multinucleated cells in vitro (Corcoran & Duncan, 2004). The rate of syncytium
formation, however, differs in HT1080 cells. Corcoran et al demonstrated significant
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syncytia at 6 hr (Corcoran & Duncan, 2004) whereas we demonstrated significant
syncytia at 8 hr post transfection. These findings establish a fusion assay suitable for
HT1080 cells to test p14 FAST protein expressions and evaluate if the p14 is fusion
active.
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Figure 3.1 Expression of p14 plasmid creates multinucleated cells (syncytia).
A) Representative images of HT1080-td-tom cells, 4, 6, 8, 12 hr following transfection
of pFastBac-p14. The nucleus was stained with a nuclear stain (DAPI) in order to
identify the number of nuclei per cell (Magnification 20 x).
B) Quantification of the number of nuclei per syncytia as measured by manual counting
of the nuclear signal (DAPI) within the HT1080-td-tom cell in the fluorescent images (5
fields of view). Syncytia formation was significantly visible after 8hr post transfection.
This data is representative of n=2 experiment and results reported as the standard means
+ standard error.
C) Immunofluorescent staining of permeabilized HT1080 syncytium 8 hr post
transfection of pFastBac-p14 using a primary p14 antibody followed by an Alex Fluor
secondary 488 antibody. The nuclei were stained with DAPI. The antibody distribution
was detected by immunofluorescent microscopy and the antibody staining revealed
intracellular p14 distribution and surface expression.
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The Insertion of a Fusion Associated Small Transmembrane (FAST) protein into an
artificial bilayer by detergent depletion method
Our initial investigation was to confirm the intracellular efficacy of fusogenic (p14)
liposomes compared to standard liposomes (no protein). Prior studies documented that
proteoliposomes containing the p14 (FAST) protein mediated liposome-cell fusion
thereby increasing cytoplasmic delivery independent of endocytosis (Top et al., 2005).
We utilized the liposome assembly protocol adapted by the Duncan laboratory, with a
lipid profile containing 1, 2-dioleoyl-sn-glycerol-3 phosphatidylcholine (DOPC), 1, 2dioleoyl-sn-glycerol-3 phosphatidylethanolamine (DOPE), dimethylaminoethanecarbamoyl cholesterol (DC-chol) and cholesterol (chol) in molar ratios of 60:30:4:6
(Table 3.1) (Top et al., 2005). The phospholipid composition has significant influence on
the bilayer fluidity and therefore an appropriate lipid formulation is used to support the
insertion of p14 (Cladera et al., 1997; Coderch et al., 2000; Top et al., 2005). Ensuring
our liposomes resemble cell membranes as closely as possible we include cholesterol, a
steroid commonly found in biological membranes (Coderch et al., 2000). Many
proteoliposomes are assembled by covalent coupling of the protein to the liposomes
surface which requires harsh chemicals. However, the insertion of this transmembrane
protein requires the addition of a detergent to solubilize the protein (Lichtenberg et al.,
1983; Paternostre et al., 1988). The purified protein was reconstituted into ~100 nm
diameter liposomes by mixing 0.9 % OG (Appendix A) suspended p14 with liposomes
presaturated with OG (Cladera et al., 1997; Petri & Wagner, 1979) followed by removal
of the detergent. To ensure elimination of the OG detergent, p14-liposomes were
subjected to SM2 Bio beads during dialysis at 4°C (Rigaud et al., 1988). To control for
the addition of the detergent, standard liposomes were also subjected to addition of OG
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and dialysis even though no protein was inserted. FITC was added to the thin film during
hydration as this is the simplest method of encapsulating hydrophilic cargo within the
liposome core. To measure the size of the liposomes after protein insertion, dynamic
light scattering (DLS) was performed. DLS analysis revealed the size of the liposomes
with or without the insertion of protein was comparable of 158.9 + 1.7 for standard and
152.1 + 1.1 for p14 liposomes (Table 3.2).

49

Table 3.1 Lipid Profile for Assembly of p14 Liposomes
Lipid

Desired
molar
ratio
(%)

Molecular
Weight
(g/mol)

DOPC
DOPE
Chol
DCChol
Total
%

60
30
4
6

786.13
744.05
386.66
501

100

%

Volume
of
Buffer
(per
flask)
(ml)
1
1
1
1

Concentration Desired final Amount
of each lipid
lipid
of lipid
solution
concentration solution
(mg.ml)
(liposomes)
required
(mM)
(μl)
25
25
25
25

20
20
20
20

377
179
12
24

Total

580

Table 3.2 Particle Size Analysis using Dynamic Light Scattering (DLS)
Liposome Group

Diameter (nm)

Standard

158.9 + 1.7

P14

152.1 + 1.1
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P14 liposomes increase intracellular FITC delivery in PC3 cells
Liposomal uptake studies were performed on PC3 cells, to test the efficiency of the p14
FITC delivery. Standard (no protein) and fusogenic (p14) liposomes were prepared and
incubated on the cells for 1hr at 4°C. The liposome preparations were incubated on the
cells at 4°C to inhibit endocytosis ensuring the FITC internalization was dependent on the
p14 fusion ability (Meulendyke et al., 2005). Liposomes were then washed off and cells
were returned to 37°C to allow internalization (Leser et al., 1996). Immunofluorescence
microscopy images (Figure 3.2A) displays a greater green fluorescence signal in the
cytoplasm of the cells incubated with the p14-liposomes. In contrast, there was a decrease
in cellular fluorescence when cells were incubated with std liposomes. To quantify the
green fluorescent signal in the cytoplasm of the PC3 cells we measured using flow
cytometry. PC3 cells incubated with p14-liposomes significantly increase the intracellular
delivery of FITC (p<0.05) (Figure 3.2B). These uptake studies verify the novel
mechanism of p14 liposomes and their ability to increase intracellular delivery
independent of endocytosis. We repeated the same experiment on two different cell
lines, breast cancer (MDA-MB231) and human fibroscarcoma (HT1080) cells to ensure
p14 liposomes increase intracellular delivery on a variety of cancer cells. Appendix B
demonstrates p14 liposomes increase intracellular delivery to three different human
cancer cells. Once confirming the fusogenic potential of p14, we developed a fusogenic
targeted fusion protein (p14-bombesin) to bind to prostate cancer cells via the GRPR.
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Figure 3.2 p14-liposomes deliver significantly more FITC to the cytoplasm of PC3
cells compared to standard liposomes.
Liposome uptake analysis of FITC, delivered by standard (Std) liposomes (no protein)
and fusogenic liposomes (p14 protein). Representative fluorescent images of one field of
view of PC3 cells at 20 X magnification. The cells were stained with a nuclear stain
(DAPI, blue) and an actin filament stain (phalloidin). The green fluorescent signal
represents the intracellular FITC uptake. B) Quantification of the fluorescence intensity
cells using Flow Cytometry. Fluorescent intensity + standard error of the mean (SEM) is
shown for the treatments and this data is representative of n=10 experiment. One way
ANOVA (P<0.05) Tukey’s Multiple Comparison Test.
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3.2 Objective 2: The creation of the p14-Bombesin peptide
and the Evaluation of the Functionality
Can a targeting ligand be attached to the C-terminus of the p14 protein to serve as a
targeting molecule for prostate cancer without disrupting the fusogenic capability of the
p14 protein?
Following confirmation that p14 increases intracellular delivery, we tested if the Cterminus will tolerate a targeting peptide. By creating multifunctional liposomes we
could increase intracellular delivery and specificity for prostate cancer.
Using PCR amplification, successful conjugation of bombesin to the C-terminus of p14
creates a targeted fusogenic construct
It has been demonstrated that the C-terminus of the p14 protein can tolerate modifications
without disrupting the N-terminal fusogenic domain (Corcoran & Duncan, 2004;
Corcoran et al., 2004). We hypothesized that conjugation of a targeting peptide to the Cterminus of the p14 protein would create a novel targeted fusogenic protein. We choose
bombesin as the targeting peptide because previous studies in our laboratory have
demonstrated the targeting ability of bombesin to the gastrin releasing peptide receptor
(GRPR) on prostate cancer cells (Steinmetz et al., 2011). We generated a p14-bombesin
fusion protein using polymerase chain reaction (PCR) amplification strategy represented
in a schematic in Figure 3.3A. Our strategy involved designing a reverse primer
containing the entire bombesin sequence. To confirm the PCR fusion of bombesin to
p14, a restriction digest was performed using Bam H1 and Xho1 restriction enzymes
(RE). The bands present in the agarose gel correlate with the respected DNA size of the
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pFastbac vector (4.7 kbp) and the p14-bombesin sequence (465 bp) (Figure 3.3B). The
DNA fragments were confirmed by sequencing at Robarts Research (Appendix C).

Expression of p14-Bombesin induces syncytia formation similar to native p14
Once we confirmed the p14-bombesin sequence, we tested the ability to induce
multinucleated syncytium formation similar to the assay we used to test the functionality
of native p14 in Objective 1. As an initial step to examine the correlation between the
rate and extent of syncytium formation, we analyzed the differences between the native
p14 and the newly created p14-bombesin. Quail fibroblast (QM5) cells were transfected
with the original pFastBac-p14 vector (positive control) and the pFastBac-p14-Bombesin.
Visualized using fluorescent microscopy the cells were stained with CellTracker green to
identify the multinucleated cell bodies. Both the p14 and p14-bombesin induced
formation of small syncytia at 6hr post-transfection which increased to larger countable
syncytia by 8hr (Figure 3.4). In summary, the addition of the bombesin sequence to the
C-terminus of p14 did not disrupt the ability to form enlarged multi-nucleated cells.
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Figure 3.3 Construction of the p14-Bombesin Fusion protein.
A) Schematic of the creation of the pFastBac-p14-bombesin. Bombesin was cloned into
the pFastbac-p14 vector between BamH1 and Xho1 by designing a reverse primer that
contained the entire bombesin sequence for polymerase chain reaction (PCR)
amplification. The p14 construct includes two tags: EK enterokinase cleavage site and
Histidine 6x (his).
B) PCR analysis of p14-bombesin was verified by digesting pFastBac-p14-bombesin
using the restriction enzymes (RE) BamH1 and Xho1 and ran on a 0.7% agarose gel in 1x
Tris/Borate/EDTA buffer (TBE) buffer. The bands correlate with the digested fragments
of pFastBac vector (4.7 kbp) and p14-Bombesin (465 bp). The p14-bombesin sequence
was confirmed using DNA sequencing technology.
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Figure 3.4 Expression of p14-bombesin results in syncytia formation similar to p14.
Epifluorescence imaging of quail muscle (QM5) cells incubated with 1 µg of pFastBacp14 and pFastBac-p14-bombesin using Lipofectamine 2000. QM5 syncytia were Cell
Tracker green stained at 8hr after transfection. Syncytia formation clearly visible in both
the p14 and p14-bombesin images.
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Calculating the syncytia index using flow cytometry approach
To determine whether the extent of syncytium formation was greater in pFastBac-p14bombesin expression, we developed a high through-put quantitative analysis to measure
the multinucleated cells by flow cytometry. To accommodate the large multinucleated
cells, we utilized a large cell Biosorter to perform our flow cytometry experiments and
stained the nuclei with Sytox green. To ensure the quantification was accurate, we
obtained samples of single events after analyzing by flow cytometry. The representative
images in Figures 3.5A display the differences between control and syncytia cells that
were sorted after the fluorescence was analyzed. The control cells contain one nucleus
whereas the syncytia cells contain many nuclei, representative of the green fluorescent
nuclei (Figure 3.5A). The flow cytometry quantification establishes no significant
difference between the syncytia formation produced by p14 or p14-bombesin expression
(Figure 3.5B). Even though there is little to know in regard to how these FAST proteins
induce membrane fusion except for the importance of the N-terminal myristoylation site,
we now confirm that the modification of the C-terminus of p14 does not alter the rate or
extent of the syncytium formation. These results support the finding made by Corcoran
et al that deletions of the C-terminus do not disrupt the cell-to-cell fusion (Corcoran &
Duncan, 2004). However, our finding differed from their study which found the
deletions delayed the rate of syncytia formation, whereas conjugating bombesin to the Cterminus of p14, did not change the rate of formation.
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Figure 3.5 Quantification of syncytia formation in QM5 cells using Flow Cytometry.
A) Representative images of the multinucleated cells, the QM5 control cells contained 1
nucleus whereas expression of the p14 and p14-bombesin contained multiple nuclei.
B) Quantification of the green fluorescent intensity correlates with the number of nuclei
present. Expression of p14 and p14-bombesin were not significantly different for
formation of syncytia.
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Purification of p14-bombesin fusion protein requires a two step process to extract
enough protein
Cobalt resin has a high affinity for his-tag on p14-bombesin protein
The baculovirus expressed p14-bombesin was purified in a two step purification process
(Top et al., 2005). The p14-bombesin sequence contains a histidine-tag for purification
purposes. Histidine is one of the most prominent affinity tags for protein purification
(Ley, et al., 2011). To purify p14-bombesin, the crude cell lysate was first incubated
with the Talon™ cobalt resin for 3hr at 4o C for initial purification to ensure total binding
of the p14-bombesin-histidine tag. Cobalt has a high binding affinity to histidine and
consequently binds to the p14-bombesin protein and other histidine rich proteins from the
crude sample (Gaberc-Porekar & Menart, 2001). The resin was washed with extraction
buffer twice to remove unbound protein and the p14-bombesin was eluted from the resin
with imidazole containing elution buffer. Imidazole is used to displace the His-tagged
p14 protein, freeing the p14 protein. The extraction of the p14-bombesin protein using
the Talon™ resin was identified by coomassie stain (Figure 3.6A). To ensure the process
extracted the p14-bombesin we loaded the extraction from the Talon compared to the
wash steps to ensure that we extracted all the p14-bombesin (Figure 3.6A).

Ion Exchange Chromatography further purifies p14-bombesin protein for a homogenous
population
To further recover the p14-bombesin protein we use a second purification step using an
ion exchange column (HiTrap Sepharose High Performance). The ion exchange column
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contains a strong cation exchange medium to bind our anionic p14-bombesin protein.
The adsorbed p14-bombesin protein is eluted using buffers varying in pH and ionic
strength to dislodge the p14-bombesin protein and collect as individual fractions and
analyzed separately (Appendix D). We assessed the ion exchange fractions using silver
stain analysis and comparing p14-bombesin purified protein to the relative migration of
the standard purified p14 protein (Figure 3.6B). In the end, approximately a total of 4 mg
of p14-bomesin protein is purified from a large scale protein batch. Despite the quantity
of purified protein, only a portion of the fractions were myristoylated and therefore
functional.
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Figure 3.6 Purification of p14-bombesin
Cell lysates of sf21 cells infected with p14-bombesin baculovirus were purified using
cobalt Talon® resin and ion exchange chromatography.
A) Proteins present were resolved by SDS-PAGE and detected by Coomassie after cobalt
resin. W1 (First wash of the resin) and the arrow indicates the p14-bombesin ~16 kDa.
B) Silver Staining after the ion exchange chromatography. Native p14 protein was used
as a standard to indicate the relative migration, W1 (first wash of the column) and the
arrow indicates the purified p14-bombesin.

61

Analysis of purified p14-bombesin using fusion assay revealed conjugation of
bombesin to the C-terminus does not disrupt the fusion motif of p14 protein
FAST proteins mediate synctyium formation and we examined the kinetics of syncytium
formation of the purified p14-bombesin protein. To test the functionality of the purified
p14-bombesin protein, QM5 cells were incubated with p14-bombesin protein delivered
with Lipofectamine, followed by fluorescence microscopy. Since expression of the
pFastBac-p14-bombesin has been confirmed to mediate cell-cell fusion, we performed a
similar assay to evaluate the functionality of the purified p14-bombesin protein.
Syncytium formation was assessed by staining the cells with CellTracker Green at 8hr
post transfection and visualized using fluorescent microscopy (Figure 3.7). The purified
p14-bombesin protein demonstrated significant syncytia formation comparable to the
fusion active standard p14, verifying that the p14-bombesin protein is functional. These
results revealed that bombesin conjugated to the C-terminus of p14 did not disrupt the
ability of p14 to induce cell-to-cell fusion and elucidates that the p14 N-terminus was
myristylated. Furthermore, the different protein fractions (Appendix D) were all assayed
for fusion activity and the representative images in Figure 3.7 was analysis of the E4 p14bombesin fraction. Most commonly protein fractions from E3 to E6 are the functional
fractions. However, the assay is perfomed on all fractions to ensure what protein
fractions are fusion active and therefore myristylated.
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Figure 3.7 Purified p14 and p14-bombesin protein forms multinucleated cells
confirming the protein is functional.
Immunofluorescence imaging of QM5 cells incubated with 4 µg of purified p14 or p14bombesin protein. Proteins were solubilized in Lipofectamine and incubated on QM5
cells for 8hr. Syncytia were visualized by staining the nuclei with DAPI (blue) and the
cytoplasm with cell tracker (green) using epifluorescence microscopy. This syncytia
assay verifies that the purified p14-bombesin protein is functional comparable to the p14
standard.
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3.3 Objective 3: Assembly of Targeted Liposomes and
assessment of FITC delivery to Prostate Cancer Cells

Targeted Liposomes Increase uptake of FITC in Prostate Cancer Cells In Vitro
The purpose of this study was to validate our hypothesis that bombesin decorated
liposomes allow target recognition to prostate cancer (PC3) cells. The targeted fusogenic
liposomes were assembled in the same manner as the p14-liposomes were in section 3.1.
For targeted delivery systems to be effective, the target should be up regulated on the
cancer cells of interest. Human PC-3 cells are a well studied cell line for gastrin
releasing peptide receptor (GRPR) targeting because they express approximately 48000
receptors per cell. To evaluate the targeted fusogenic properties of the p14-bombesin
protein-containing liposomes, we encapsulated a fluorescein isothiocyanate (FITC) (1
mg/mL) inside cationic liposomes, standard (no protein), fusogenic (p14 protein) and
targeted fusogenic (p14-bombesin protein). We incubated the liposomes on PC3 cells for
1hr at 40C and measured the uptake of FITC using confocal microscopy and flow
cytometry. Figure 3.8 is representative fluorescent confocal microscopy images of PC3
cells and the green fluorescence (FITC) intensity is indicative of the efficiency of the
different treatment groups as the targeted (p14-bombesin) liposomes exhibit a greater
distinction in the cytoplasm of the PC3 cells. Untargeted liposomal treatments had
significantly less FITC accumulation in PC3 cells (Figure 3.8). According to Figure 3.8,
targeted liposomes significantly increase the FITC uptake into PC3 cells compared to
both standard liposomes (no protein) and fusogenic liposomes (p14) (P<0.05).
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Furthermore, p14-liposomes also had significantly more FITC compared to standard
liposomes, confirming that p14 increases the intracellular delivery.
The flow cytometry results were reflected in the fluorescence images captured by the
confocal microscopy. Flow cytometry histograms are presented in Figure 3.9A and the
quantification in Figure 3.9B reveals the FITC expression is very consistent with the
fluorescent microscopy images. In summary the GRPR are an attractive target for the
navigation of therapeutics because the receptors are widely expressed on the surface of
prostatic cancers. Moreover, these results establish that the addition of bombesin peptide
to p14-liposomes enables successful targeting of PC3 cells increasing the intracellular
delivery beyond that of the fusogenic liposomes.
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Figure 3.8 p14-bombesin liposomes increase the intracellular delivery of FITC to
PC3 cells.
Fluorescence confocal microscopy images of p14-bombesin, p14, or standard liposomes
encapsulating FITC incubated with PC-3 prostate cancer cells. Nucleus (DAPI stain) and
actin filaments (phalloidin stain). These images were taken at 63 x magnification with an
oil surface.
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Figure 3.9 p14-Bombesin Liposomes Significantly Increase FITC in PC3 cells
A) Histogram of FITC signal using flow cytometry of PC3 cells incubated with
liposomes. B) Quantification of uptake of liposomes into PC3 cells using flow cytometry.
Mean percentage of the green fluorescent positive cells +standard error of the mean
(SEM) is shown for each treatment. P14-bombesin is take up more efficiently than p14liposomes (p<0.05). This flow cytometry data is representative of n=8 experiment with at
least 10000 events collected. One way ANOVA (P<0.05): Tukey’s Multiple Comparison
Test.
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P14-Liposomes are internalized within PC3 cells and not bound to the cell surface
The previous study we studied the binding and uptake of the p14-bombesin liposomes to
PC3 cells by measuring the fluorescence of the cell with flow cytometry. However, this
method does not definitely distinguish between the liposomes bound to the surface or
intracellularly. Using confocal microscopy and imaging using 3D stacks, we were able to
distinguish the localization of the FITC in PC3 cells following p14-bombesin liposomal
treatment. The 3D representative images in Figure 3.10 demonstrate the presence of the
FITC (green fluorescence) located between the actin filaments of the cell membrane
(orange fluorescence) confirming the internalization of the FITC. Attachment of the
bombesin peptide did not alter the p14 ability to induce liposomes to cell fusion allowing
direct cargo delivery to the cytoplasm of the cells.
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Figure 3.10 p14-Bombesin Liposomes Deliver FITC Intracellularly into Prostate
Cancer Cells (PC3 cells).
Fluorescence confocal microscopy 3-dimensional images of p14-bombesin liposomes
incubated on PC3 cells. A) Separate channels; green (FITC), orange (actin filaments of
the cytoplasm), blue (nuclear stain) B) the orientation of the cross-section C) Crosssection (confocal z stack) demonstrating the intracellular FITC signal.
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3.4 Objective 4: Evaluation of the Specificity of Bombesin
Targeted Liposomes

Testing the uptake of Targeted Liposomes on Benign Prostatic Hyperplasia cells
After we established p14-bombesin liposomes significantly increased the FITC uptake in
PC3 cells, we determined if this targeting is explicit for cells with a high density of
GRPR. To verify the expression of GRPR we used Western blot analysis in different
prostate cells, human prostate cancer cell line (PC3) and a non-cancerous benign prostatic
hyperplasia (BPH) cell (Figure 3.11A). Bands of tubulin were used as a loading control
for the normalization of the GRPR bands. PC3 cells demonstrated a higher expression of
the GRPR compared to the BPH cells, verifying that the PC3 cells were an adequate cell
line to test the targeting potential of the p14-bombesin liposomes. Since BPH cells have a
lower GRPR protein expression (Figure 3.11A); we used these cells to perform the same
experiment as we did on the PC3 cells which over expressed the receptor. The uptake of
FITC liposomes in BPH cells, with no protein, p14, or p14-bombesin was evaluated by
flow cytometry (Figure 3.11B). Compared to the analysis in PC3 cells, the uptake in
BPH cells differed only in the p14-bombesin treatment. There was a significant decrease
in FITC uptake of the p14-bombesin liposomes in contrast to the p14 liposomes (p<0.05).
This is due to the lower GRPR expression in the BPH cells and therefore the p14bombesin liposomes did not bind to the BPH cells at the same efficiency as they did on
PC3 cells which exhibited a higher receptor density. Furthermore, the standard and p14
liposomes had similar FITC uptake comparable to PC3 cells. This is the first evidence
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that supports the hypothesis that p14-bombesin liposomes show an increased avidity for
GRPR expressing PC3 cells.
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Figure 3.11 p14-Bombesin Liposomes Did Not Target Benign Prostatic Hyperplasia
Cells
A) Western blot analysis of the protein expression of the gastrin releasing peptide
receptor (GRPR) in prostate cancer cells (PC3) and the benign hyperplasia cells (BPH)
and tubulin was used a loading control.
B) Quantification of uptake of the liposomes into PC3 cells using flow cytometry. Mean
fluorescent intensity + standard error of the mean (SEM) is shown for each treatment.
P14-bombesin liposomes are taken up less efficiently in BPH cells which have a lower
protein expression of the receptor, than PC3 cells. This flow cytometry data is
representative of n=5 experiment with at least 10,000 events collected. One way
ANOVA (P<0.05): Tukey’s Multiple Comparison Test.
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Receptor blocking decreased liposomes decorated with bombesin to PC3 cells
To dissect the targeting ability, in more detail, we performed a receptor block analysis.
We have previously reported the bombesin peptide manufactured by the Luyt lab is
specific for the GRPR (Steinmetz, et al., 2011). To ensure that the ligand was mediating
the binding of the peptide functionalized fusogenic liposomes to prostate cancer cells,
PC3 cells were incubated with an excess of free bombesin peptide for 10 min prior to
incubation with the liposomes. Flow cytometry analysis resulted in a significant decrease
in uptake of the p14-bombesin liposomes in PC3 cells (P<0.05) (Figure 3.12). In
addition, adding the free bombesin peptide to cells incubated with standard and p14
liposomes did not change the uptake of FITC. The flow cytometry results indicate free
bombesin peptide effectively blocks the functionalized fusogenic liposomes from binding
to the GRPR in PC3 cells, supporting the hypothesis that p14-bombesin liposomes
specifically target prostate cancer cells.
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Figure 3.12 Receptor Blocking
Quantification of uptake of liposomal FITC into PC3 cells using flow cytometry. P14bombesin liposomes were effectively blocked by an excess of free bombesin peptide,
however the free bombesin peptide did not change the uptake in the other treatment
groups (Std and p14). This flow cytometry data is representative of n=2 experiments with
at least 10 000 events collected, FITC positive cells + standard error of the mean (SEM)
is shown for each treatment.
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Knockdown of the GRPR Decreased Liposomes conjugated with Bombesin to PC3 cells
Furthermore, to display the preferential association for GRPR expressing cells, we
evaluated the uptake of p14-bombesin liposomes on PC3 cells with a lower GRPR
expression. We used small interfering RNA (siRNA) technology to knockdown the
GRPR in PC3 cells. Transfecting 20 nM GRPR siRNA we decreased the GRPR
expression in PC3 cells. Although the transfection only resulted in partial knockdown,
validated by Western blot analysis (Figure 3.13A), we can significantly decrease the
FITC uptake of p14-bombesin liposomes compared to uptake in normal PC3 cells (Figure
3.13B). Due to the inability to completely knockdown the receptor, the FITC uptake of
p14-bombesin liposomes in siRNA transfected PC3 cells remained significantly higher
than the uptake of p14 liposomes. Despite this result, the findings demonstrate a decrease
in uptake once the GRPR protein expression was lowered. Together, these results confirm
liposomes targeted with bombesin peptide showed a significant preference to associate
with PC3 target cells over PC3 cells with a lower GRPR expression.
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Figure 3.13 Knockdown of GRPR in Prostate Cancer cells Decreases p14-Bombesin
uptake
A) Western blot analysis of the protein expression of the gastrin releasing peptide
receptor (GRPR) in prostate cancer cells (PC3) and tubulin was used as a loading control.
PC3 cells transfected with a negative siRNA and 20 nM of GRPR siRNA.
B) Quantification of uptake of the liposomes into PC3 cells using flow cytometry.
Knockdown of the GRPR, using 20 nM siRNA effectively decreased the uptake of the
p14-bombesin liposomes. This flow cytometry data is representative of n=3 experiment
with at least 10 000 events collected and FITC positive cells + standard error of the mean
(SEM) is shown for each treatment. One way ANOVA (P<0.05): Tukey’s Multiple
Comparison Test.
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3.5 Objective 5: Evaluate the Intracellular Delivery of
Nucleic Acids

WS improves Encapsulation of Nucleic Acids
In this study, we used a previously described “wrapsome” (WS), designed with a core
composed of a cationic lipid bilayer DOTAP (1, 2-dioleoyl-3-trimethylammoniumpropane) and pcDNA 3.1-GFP plasmid enveloped in the identical lipid bilayer used in the
above experiments (Table 3.1). WS efficiently packages the nucleic acid without
exposing the negatively charged DNA on the outer surface (Yamauchi, Kusano, Saito,
Iwata, Nakakura, Kato, Uochi et al., 2006). We predicted that the addition of the
DOTAP core would encapsulate more DNA than the lipid formulation we used in
previous experiments. In spite of this, we were apprehensive how the p14 protein
insertion process (detergent depletion) would affect these novel wrapped liposomes or if
the WS would change the OG %. We determined that the inner DOTAP core had no
obvious differences then liposomes without DOTAP, as we used a 0.9% OG for insertion.
At the start of the preparation, 100 µg of DNA (measured by a spectrometer) diluted in
1X PBS was added to the dried 5.6 mM DOTAP film. The DOTAP concentration was
determined by using a calculation employed to have an equal charge ratio of DNA:
DOTAP. Thus, the concentration of DOTAP changes with differing amounts of DNA
(Appendix E).
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DNA Quantification with Heparin
In previous research, the stability of DOTAP-DNA complexes inhibits the interaction of
DNA binding or intercalating agents (Moret et al., 2001). Ethidium bromide (EtBr) and
Picogreen are fluorescent probes commonly employed to quantify DNA by measuring the
fluorescence intensity. However, these probes are unable to bind to DNA when
complexed with DOTAP. In order to release the DNA from DOTAP, polyanionic
heparin was assayed. When heparin was added in a final concentration of 12.5µg/µl
(determined from Appendix F) both the EtBr and Picogreen could bind to the DNA.
Agarose gel electrophoresis demonstrated that DNA was released from DOTAP in the
presence of heparin. When DNA was mixed with DOTAP the release was 100% whereas
the release of the DNA encapsulated within the DOTAP core was slightly lower which
suggests an incomplete release of DNA from the DOTAP (Figure 3.14A).
Picogreen was used to confirm the above results. Similar fluorescence intensities
obtained with free DNA and free DNA mixed with DOTAP (Figure 3.14B). In the
process of generating DNA encapsulated within DOTAP, we achieved ~75% DNA
incorporation, similar to the results above (Figure 3.14). In summary, the DNA was
efficiently encapsulated suggesting that a charge interaction between the negatively
charged DNA and positively charged DOTAP assisted the efficiency in loading.
Moreover, the addition of heparin assisted in the release of DNA from DOTAP to assess
an approximate amount of DNA encapsulated, however not an exact determination
(Appendix G).

78

Figure 3.14 Heparin releases DNA from the DOTAP
A) Influence of DOTAP on DNA migration in a 0.7% agarose gel containing Ethidium
Bromide (Et Br). The free/ naked pCDNA 3.1 GFP migrated normally. Lanes 2&3,
pCDNA 3.1 GFP incubated with DOTAP in the same concentration as the GFP
encapsulated within the DOTAP (lanes 6&7). The + indicated the addition of 12.5 µg/µl
Heparin for 10 min prior to adding to the gel. Once Heparin was added to both DNA
incubated with DOTAP and DNA encapsulated within DOTAP, the bands had migrated
and the Et BR was able to bind to the DNA.
B) Quantification of pCDNA 3.1 GFP using Pico Green nucleic acid stain measuring the
fluorescent intensity in the presence of heparin (12.5 µg/µl and 25 µg/µl).
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Transfection Efficiency of p14-WS
To assess the distribution of DNA delivered by WS within human fibrosarcoma
(HT1080) cells, we examined the transfection efficiency of a green fluorescent protein
(GFP). Transfections were performed under identical conditions to determine the
difference between standard and p14 WS compared to a transfection reagent. We chose
Lipofectamine as a positive control as it is a cationic lipid reagent commonly used for in
vitro DNA transfections. The transfections between p14 and std WS were negligible at
24hr, resulting in green fluorescence comparable of about 1 GFP positive cell/field of
view (Figure 3.15). However, at 48hr post transfected p14 observed to have more GFP
positive cells (Figure 3.16). As expected, DNA mixed with Lipofectamine had higher
transfection efficiency. Previous studies revealed that cationic carriers are quite toxic to
cells. However, it is unknown as to what affect other liposome preparations have on the
morphology of cells. To test the toxicity of the different liposomal transfection reagents,
we did not remove the DNA transfection solutions. Light microscopy was used to
determine the outcome of the different liposomal treatments on the cell morphology.
Cells exposed to WS were similar in morphology to control cells, whereas healthy
looking cells were less apparent following incubation with cationic Lipofetamine (Figure
3.15). In general, cationic lipids increase unfavorable changes in cellular morphology
whereas the WS did not subject the cells to toxic effects. Although this study is limited
by the lack of statistical data, the preliminary results indicate an efficient method of
encapsulating negatively charged nucleic acids and transfection efficiency with lowered
toxic effects.
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Figure 3.15 24hr GFP Transfection Efficiency
Human fibrosarcoma (HT1080) cells transfected with GFP plasmid by Lipofectamine
(positive control), Std WS (no protein), and p14 WS. Control cells were used a negative
control. Representative fluorescent microscopy images at 24 hr post-transfection.
Transfection reagents were not replaced with fresh medium to visualize the toxicity of the
reagents. Lipofectamine reagent clearly changed the morphology of the cells compared
to control cells.
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Figure 3.16 48hr Transfection Efficiency of Std and p14 Wrapsomes (WS)
Representative fluorescent microscopy images of human fibrosarcoma (HT1080) cells
transfected with GFP plasmid using Std or p14 WS (no protein), and p14 WS at 48hr.
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Chapter 4

4

Discussion

4.1 General Discussion and Implications

Prostate cancer remains the most common malignancy in North American men and
despite current treatment options, such as radical prostatectomy and active surveillance
the therapeutic choices are limited for preserving the quality of life for patients (Bangma,
2011; Canadian Cancer Statistics, 2011). For advanced prostate cancer, chemotherapy is
an unfavorable treatment option because the cytotoxicity of available drugs gives rise to
unwanted side effects. To counteract this predicament, liposome drug vehicles increase
pharmacokinetics and bioavailability by passive targeting through the EPR effect and
furthermore, liposomes decrease non-selective toxicity (Matsumura & Maeda, 1986).
However, apart from recent advancements, liposomal drug delivery is still inadequate for
efficient intracellular delivery. A major obstacle for liposomes is the cell membrane
barrier which encumbers the penetration of particles and ultimately impedes the cargo
delivery to the cell cytosol. Consequently, the “fusogenic entities” have only overcome
this impediment by incorporating different elements which allows the liposomes to
escape from the natural endosomal pathway. Endosomal release strategies held great
promise to increase cytosolic delivery however the results were sub-optimal (Sakurai et
al., 2011; Zhou & Huang, 1994; Zuhorn et al., 2005). Despite decades of research, many
liposome formulations do not penetrate the cell membrane and are limited to entry
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through endocytosis. The discovery of p14 liposomes is the first to our knowledge a true
fusogenic liposome that exhibits fusion capabilities on the cell membrane. A fusogenic
liposome carrier would be a beneficial means to deliver therapeutics that could be taken
to the clinics. Studies involving the p14 protein reconstituted into liposomes have
provided encouraging results in vitro. In the present study, we report the validation of a
fusogenic protein, p14, which enhances the intracellular delivery bypassing the
degradative pathway. The FAST proteins have exceptional structural features and
therefore when p14 is reconstituted into an artificial lipid bilayer, the p14 can mediate
liposomes to cell fusion. We demonstrated that p14 liposomes increased intracellular
FITC compared to standard liposomes on a variety of human cancer cells. This
experiment verified that the uptake was independent of endocytosis predominantly due to
the fusion motif on p14. This is in accordance with the experiments conducted by Mader
et al in which they demonstrated that p14-liposomes increased the LfcinB delivery
compared to standard liposomes (Mader et al., 2007). These results concur with the
proposed mechanism depicted in Figure 1.1 and provide evidence that p14-liposomes
bypass the endocytic pathway by virtue of the fusogenic domain on the N-terminus of
P14. Taken together, the fusion activity of p14 verifies the unique feature of this
transmembrane protein which increases intracellular delivery but also act as an anchor to
attach a targeting peptide.
Prostate cancer targeted nanoparticles conjugated with bombesin have demonstrated both
in vitro and in vivo active targeting results. Previous research in our lab has demonstrated
the feasibility of using the small amphibian tetrapeptide to target nanoparticles to human
prostate cancer cells in vitro. We have also established anti-tumour activity of targeted
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particles in an avian embryo model of PC3 cells (Steinmetz et al., 2011). Therefore,
active targeting via the bombesin peptide may provide the assistance to overcome hurdles
facing therapeutic delivery to prostate cancer. Taken together, we decided to combine
the two objectives of research in a single moiety to evaluate the potential of PC3 specific
p14-bombesin peptide as a navigating ligand. The justification behind the use of the two
unique entities lies in the caveats outlined in the introduction. Liposomes assembled in
this study contained a fusogenic domain allowing direct entry into the cell bypassing the
endosomal uptake and secondly, liposomes were decorated with bombesin to actively
target prostate cancer cells. Furthermore, bombesin did not require chemical conjugation
for attachment to the liposomes surface. Instead the transmembrane p14-bombesin
protein was inserted directly into the artificial bilayer.
Liposomes functionalized with a targeting moiety have great potential to achieve tissue
and organ targeting. A key challenge in development of targeted liposomes is the
capacity to attach and display the targeting entity on the particle. The ultimate goal of the
project was to create a targeted-FAST peptide that would not disrupt the fusogenic
properties of the p14 protein, but would target prostate cancer cells as well. For the first
time, we present a detailed report on how to develop a p14 targeted protein to incorporate
into liposomes. Evidence demonstrates that attachment of bombesin to the C-terminus of
the p14 protein does not disrupt the functional capability and supports the findings found
by Corcoran et al in the deletion studies of the C-terminus (Corcoran et al., 2004).
However, unlike Corcoran et al who recognized that deletion of amino acids at the Cterminus decreased the rate of syncytium, we discovered that conjugation of bombesin to
the C-terminus did not (Corcoran et al., 2004). P14-bombesin was able to create syncytia
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in both functionality tests; vector transfection and protein assays. Furthermore, the
attachment of bombesin did not change the properties of protein insertion and therefore
the original OG detergent depletion method was used. Moreover, the SM2 Bio Beads
used during dialysis did not inactivate the fusion moiety of p14 as Metsikko et al
indicated in their study (Metsikko et al., 1986). Giving rise to the concept, that the Cterminus of p14 will tolerate the conjugation of a targeting peptide without destroying the
fusogenic capability of the p14 FAST protein. Thus, p14 is a promising asset to targeted
liposomal therapy, due to its tolerance of a targeting entity on the C-terminus.
We hypothesized that anti cancer therapeutics delivered in molecular targeted fusogenic
liposomes will increase intracellular delivery and specificity for prostate cancer cells.
Indeed, we found that the p14-bombesin liposomes did target PC3 cells specifically
compared to non-cancerous BPH cells. In addition, bombesin conferred specific binding
to the GRPR verified by receptor blocking analysis and silencing of the receptor.
Although the methodology employed was not completely novel, the attachment of a
targeting peptide to the p14 was a distinct feature. While fusogenic liposomes have
provided an efficient tool for intracellular delivery, the incorporation of a targeting
peptide allows for specific tissue and organ trafficking. In this study, we have engineered
a functional navigating drug delivery system capable of targeting the GRPR expressing
cells which is further strengthened by efficient intracellular delivery via the functional
p14.
Delivery of DNA and siRNA has gained the attention of many researchers. The
possibility to transport these nucleic acids would create a new generation of therapeutics.
DNA vaccines have been used for decades, however if an adequate carrier could shield
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the DNA from degradation in vivo the possibilities are endless. Wrapsomes have
demonstrated a new class of liposomes possible to efficiently encapsulate the negatively
charged amino acids. Herein, we describe preliminary evidence of the use of the
platform in conjugation with the p14 peptide to further increase the efficacy of this
delivery module. Wrapped Liposomes involves exploiting the cationic lipid nature to
bind with the anionic DNA and wrapping this core within another lipid bilayer for
fabrication of an unique wrapsome. We in turn capitalized on this distinctive
encapsulation strategy and inserted our p14 protein to increase the efficacy of WS. We
demonstrated that the key potential of WS was to not only entrap enough DNA to exert
an effect on target cells but to decrease toxicity seen with traditional transfection
reagents. Our very early studies indicate the potential of using the p14 protein to increase
the delivery of nucleic acids. In this dissertation we provided evidence of delivery of
DNA, however, the possibility of siRNA delivery is also capable. Therefore, the advent
of this nanotechnology has provided key improvements to nucleic acid delivery in hopes
of contributing to the therapy of human disease.

Limitations
Although this study has provided in vitro “proof of principle” evidence that p14bombesin liposomes target PC3 cells, there are drawbacks associated with the lack of in
vivo studies. Assessing the active targeting of the liposomes to the prostate cancer in an
animal model would allow us to conclude that the p14-bombesin liposomes navigate
specifically to prostate cancer specifically. The assessment of a therapeutic moiety is
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needed to test the efficiency of the drug delivery platform. Finally, in vivo studies should
be preformed to compare the tumour targeting and tumour growth inhibition.

4.2 Future Directions and Clinical Implications

Based on the above finding, the results of the current study contributed to a novel
therapeutic platform for specific targeting of prostate cancer as well as successful
intracellular delivery. These results have demonstrated that a targeting peptide can be
conjugated to the C-terminus of the p14 protein and therefore creates endless
opportunities to target other diseases organs and tissues. Using similar approaches
baculovirus platforms could express a variety of targeting constructs. Other examples of
targeting ligands to conjugate to p14 are Rb_p or RGD peptides. These peptides have
been investigated to target tumour endothelial cells in angiogenic vessels within solid
tumours by binding to integrins (Arap et al., 1998). Using these integrins we could
target any type of tumour by directing the fusogenic liposomes to the endothelial of
tumour vessels. Furthermore, with this therapeutic platform we could create liposomes
that contained different targeting agents within one liposome population. Conjugating
different targeting peptides, such a tumour targeting agent (bombesin) and an angiogenic
integrin (RGD), liposomes would target both the tumour and the vasculature.
Non-invasive imaging would be greatly advantageous to monitor the targeted delivery of
therapeutic agents as it would allow the real-time evaluation of biodistribution and
tumour uptake. Furthermore, non-invasive modalities such as positron emission
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tomography (PET) and single photon emission computed tomography (SPECT) would be
useful to image the uptake of liposomes in prostate cancer. Creation of a dual noninvasive imaging and drug delivery system using liposomes labeled with radioisotopes
such as 111In. would allow the study of biodistribution of the prostate directed fusogenic
liposomes using SPECT and/or PET imaging.
The administration of a gene of interest successfully results in expression of the
therapeutic protein and thus the delivery of the large anionic DNA across the cell
membrane is the most difficult endeavours. Wrapsomes have proved to deliver intact
anionic nucleic acids and therefore this recombinant DNA technology has created
opportunities for gene therapy for other diseases such as arteriosclerosis, cystic fibrosis,
and other genetic disease. Using this unique lipid formulation that protects the nucleic
acids from degradation in vivo also allows the opportunity to deliver siRNA.
Targeted technology encourages earlier deployment of therapeutics to treat prostate
cancer which can increase the therapeutic index while decreasing side effects. There is
an evident need for targeted therapy of prostate cancer to direct therapeutics to the site of
cancer development. This research provides preliminary evidence of an effective
alternative to current liposomal chemotherapy. This targeted fusogenic model would also
be useful for the administration of other pharmacological agents and could also be used
for non-invasive imaging. The targeted fusogenic liposomes engineered in this study has
the potential to target disease sites while also penetrating the impermeable cell
membrane, a “Swiss Army Knife” of liposomal carriers.
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Appendix

Appendix A Analysis of the % OG need to insert the p14 protein
Differing concentrations of n-Octyl b-D-glucopyranoside (OG) was added to liposomes
and the optical density (OD600) was measured. This assay determines the necessary
amount of OG to change the fluidity of the lipid membrane without solubilizing the
liposomes.

102

Appendix B p14-Liposomes increase intracellular FITC delivery
Liposome uptake analysis of FITC, delivered by standard (Std) liposomes (no protein)
and fusogenic liposomes (p14 protein). Representative fluorescent images of one field of
view of A) MDA-MB-231 and B) HT1080 cells at 20 X magnification. The cells were
stained with a nuclear stain (DAPI, blue) and an actin filament stain (phalloidin). The
green fluorescent signal represents the intracellular FITC uptake.
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Appendix C Confirmation of the p14-Bombesin Sequence.
P14-bombesin sequence was confirmed by DNA analysis at Robarts Research Institute.
The sequence in black corresponds to the original sequence generated by Vector NTI ®
Software (Invitrogen) including the enterokinase site (purple highlight), histidine tag
(green highlight), bombesin (yellow highlight) and the stop codon (TAA). The sequence
in purple represents the forward sequencing and the green base pairs represents the
reverse sequence returned from the Robarts. Verifying bombesin was successfully
cloned to the C-terminus of p14.
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Appendix D Silver Stain analysis of the different fractions eluted from the ion
exchange column from varying the ionic strength and pH of the buffers.
Aliquots 7 ug of protein (per elution) were analyzed using SDS-PAGE and protein bands
were visualized by silver staining. Native p14 was used as a standard (p14 std) to
indicate the relative migration. Lanes E4 – E8 show typical elution profile of purified
p14-bombesin.
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Appendix E Calculation to determine the concentration of DOTAP to the amount
of DNA present to result in a 1:1 ratio
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Appendix F Determination of heparin concentration to displace DNA from the
DOTAP using PicoGreen fluorescent analysis
Increasing the concentration of heparin to 125 μg/μl did not increase the amount of DNA
released from the DOTAP core compared to 8μg/μl. Any concentration from 8-125 μg/μl
will sufficiently displace DOTAP exposing DNA to bind to fluorescent probes for
quantification.
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Appendix G Calculating DNA encapsulation efficiency in WS
Picogreen DNA analysis using heparin to displace DOTAP from the DNA, WS had
~50% encapsulation efficiency. This assay is not qualitative as the displacement of
DOTAP is not definite and thus remains to interfere with the assay.
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